Jae Young Chang, a Partner in SHIN & KIM’s Medical and Pharmaceutical Team, presented on the topics of “Structuring and Other Considerations for License Agreements / M&A and Investment in the Medical and Pharmaceutical Sector” at a seminar that was hosted by the Healthcare Committee of the In-House Counsel Forum (IHCF) on April 18, 2014.
The seminar was attended by over 50 IHCF in-house counsel and Healthcare Committee members, and Mr. Chang was commended for the very practical approach he took in explaining his points with real-case experience and precedents on: the meaning and structuring of license agreements and considerations for each clause; and with regard to M&A, transaction structuring, due diligence considerations and the drafting and review of contracts.
Mr. Chang has represented numerous medical and pharmaceutical companies in their M&A, joint venture and equity investment deals, advising on: confidentiality agreements, material transfer agreements, license agreements and supply agreements, among others, for pharmaceutical and medical equipment companies; corporate governance improvement for pharmaceutical companies, such as transitioning to holding companies; state-run organizations’ entry into the overseas medical markets; and acquisitions of pharmaceutical and medical equipment companies and overseas hospital management companies.
In October of 2013, the Medical and Pharmaceutical Team of SHIN & KIM and the Korea Pharmaceutical Manufacturers Association hosted a seminar on “Legal Issues in the Drug Approval-Patent Linkage System and the Parallel Import of Medical Products,” suggesting measures for reconciling the competing interests of concerned parties in the process of adopting the new system and steering the system in a more constructive direction. The seminar was viewed to have provided in-house counsel in the medical and pharmaceutical sector with useful information on a timely subject matter.